FDAsafety guidance66% confidence
Phase 1 Investigational New Drug (IND) Navigator
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Annora Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
The Phase 1 IND Navigator provides the tools, guidances, and regulatory expertise you need to prepare and submit an successful Investigational New Drug (IND) application.
Supporting Context
- Therapeutic area
- Hematology · Spleen Tyrosine Kinase Inhibitor
- Sub-indication
- General
Related signal: FDA Grants Approval for Fostamatinib Disodium ANDA217329